Palatin Technologies (PTN)
(Real Time Quote from BATS)
$2.03 USD
-0.04 (-1.93%)
Updated May 16, 2024 12:46 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 41 - 60 ( 196 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
PL9643 Officially Going Pivotal in DED With FDA On Board
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Highlights Expanding Portfolio of MCR Agonists; DED Phase 3 on Deck
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q21 Results; Vyleesi Hitting Stride Ahead of Likely Partnership; ''9643 About to Go Pivotal
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q21 Results; As Vyleesi Rebuilds, Potential Around Other Assets Crystallizes
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Dry Eye Disease Goals Achieved; Path to Registration is Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q21 Results; Data and Hopefully a Partnership Coming Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2020 Results; Eyes Toward Vylessi Re- Licensing; Opportunity Remains After AMAG Drama
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
PL9643 Completes the Enrollment of DED Patients; Phase 2 Data Expected in 4Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Free at Last; Vyleesi Now Sitting Pretty for Next Steps
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Palatin Joins the Fight Against COVID-19-Induced Lung Injury With PL8177
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q20 Results; Waiting on Vyleesi Visibility; PL9643 Remains on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
PL9643 Enters the Clinic to Tackle Dry Eye Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q20 Results; Waiting for Vyleesi to Find Proper Home
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
AMAG Drama Continues; Target Lowered to $2 Pending Vyleesi Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q20 Results; Vyleesi off to an Early but Impressive Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2019 Results; Vyleesi Now Being Marketed; Focus on Key Pipeline Expansion
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
The Time Has Come for Vyleesi; Next Chapter Begins Plus a $60M Check; Target Increased to $7.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
AMAG Highlights Vyleesi''s Commercial Profile at Analyst Day; Stage Set for 3Q19 Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
AMAG Highlights Vyleesi''s Commercial Profile at Analyst Day; Stage Set for 3Q19 Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
It''s Time to Get Excited; Vyleesis PDUFA Is June 23; Target Increased to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J